Case Reports

Superior vena cava syndrome as an initial presentation of low-grade follicular lymphoma


 

Superior vena cava (SVC) syndrome refers to a constellation of symptoms produced by the obstruction of blood flow through the SVC, resulting in symptoms of dyspnea, facial and upper-extremity edema, cough, chest pain, and dysphagia.1 Malignancies represent 60%-85% of the etiologies of SVC syndrome. Cumulatively, lymphoma and lung cancer represent 95% of malignancy-related SVC syndrome etiologies, with non-small-cell lung cancer (NSCLC) reported in about 50% of cases, small-cell lung cancer (SCLC) in about 25%, and non-Hodgkin lymphoma (NHL) in 10 % of all cases.1,2

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Thumbs-up on laparoscopic splenectomy for malignancies
MDedge Hematology and Oncology
FDA panel votes against panobinostat as add-on therapy for multiple myeloma
MDedge Hematology and Oncology
Infection may cause implant-associated ALCL
MDedge Hematology and Oncology
Hospice cuts cost and use of care for cancer patients
MDedge Hematology and Oncology
Group develops cancer health literacy tool
MDedge Hematology and Oncology
Hematology drugs on the fast track
MDedge Hematology and Oncology
Aspartame, sweetened drinks don’t increase risk of NHL
MDedge Hematology and Oncology
NICE recommends ofatumumab in CLL
MDedge Hematology and Oncology
Speaker advocates chemo-based salvage in HL
MDedge Hematology and Oncology
Brentuximab tops chemo in HL, doc says
MDedge Hematology and Oncology